Key Takeaways
- Repligen has agreed to acquire BioLife Solutions through a mixed cash-and-stock transaction valued at approximately $1.5 billion
- Shareholders of BioLife will receive $11.25 in cash alongside 0.1442 shares of RGEN stock per share ā representing a 6.2% premium over the previous closing price, equating to $31 per share
- The transaction is projected to boost adjusted EPS by no less than $0.05 in the first year and $0.25 in the second year
- Cost synergies are anticipated to reach a minimum of $20 million in year one, climbing to $30 million by year two
- The transaction is scheduled to finalize in Q4 2026, contingent upon regulatory clearance and shareholder consent
Shares of Repligen (RGEN) tumbled approximately 5.84% during Wednesday’s trading session following the company’s announcement of its plan to acquire BioLife Solutions (BLFS) in a transaction valued at roughly $1.5 billion.
The acquisition structure consists of 64% Repligen stock and 36% cash consideration. Under the terms, BioLife shareholders will be entitled to $11.25 cash per share alongside 0.1442 shares of RGEN for every share held. This establishes an aggregate value of $31 per share ā marking a 6.2% premium above BioLife’s most recent closing price.
The deal has received unanimous approval from both companies’ boards of directors. Completion is anticipated during the fourth quarter of 2026, pending requisite approvals from shareholders and regulatory bodies.
According to Repligen, the acquisition will enhance adjusted earnings per share by a minimum of $0.05 during the first year post-closing and by at least $0.25 in the second year. The company intends to finance the cash component using existing cash reserves and anticipates maintaining over $300 million in pro forma cash following transaction completion.
Management forecasts cost synergies of no less than $20 million in the initial year after closing, escalating to a minimum of $30 million by year two. These efficiencies are expected to stem from eliminating public-company overhead costs, streamlining general and administrative operations, and optimizing the supply chain.
Strategic Assets in the Acquisition
BioLife’s principal offering is its biopreservation media platform, anchored by CryoStor. This product suite currently supports 18 commercially approved therapies and serves the vast majority of commercially sponsored cell-based therapy clinical trials in the United States.
The acquisition also delivers a comprehensive portfolio of cell-processing instruments and a high-margin consumables business generating recurring revenue. According to Repligen, the combined entity will enhance its ability to serve cell therapy customers comprehensively, including strengthening its market position in the Asia Pacific region.
BioLife had been simplifying its operations prior to this agreement. In October 2025, the company divested its evo cold-chain logistics division for $25.5 million, refocusing its strategy on cell and gene therapy instrumentation.
Financial Performance Overview
Repligen disclosed preliminary Q2 2026 revenue expansion of roughly 12% to 13% on an organic basis. Meanwhile, BioLife’s preliminary Q2 revenue demonstrated approximately 21% year-over-year growth.
This transaction follows remarks from Danaher on Tuesday indicating a rebound in bioprocessing demand, as biotechnology and pharmaceutical companies ramp up expenditures following an extended period of subdued research activity and inventory corrections.
The announcement arrives approximately one month after German pharmaceutical giant Merck KGaA revealed an $11.3 billion agreement to acquire Bio-Techne, another instrumentation provider in the drug development sector.
Repligen’s CEO Olivier Loeillot described BioLife’s product portfolio as “highly differentiated” and emphasized that the acquisition strengthens its current cell therapy capabilities. BioLife’s CEO Roderick de Greef characterized Repligen as an “ideal partner” due to its worldwide commercial infrastructure and synergistic technology offerings.
RGEN declined 5.84% while BLFS advanced 0.34% during early Wednesday trading activity.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
